Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Emerging MEK inhibitors.
McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. McCubrey JA, et al. Among authors: stivala f. Expert Opin Emerg Drugs. 2010 Jun;15(2):203-23. doi: 10.1517/14728210903282760. Expert Opin Emerg Drugs. 2010. PMID: 20151845 Review.
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA. McCubrey JA, et al. Among authors: stivala f. Biochim Biophys Acta. 2007 Aug;1773(8):1263-84. doi: 10.1016/j.bbamcr.2006.10.001. Epub 2006 Oct 7. Biochim Biophys Acta. 2007. PMID: 17126425 Free PMC article. Review.
Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.
McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, Wong EW, Lehmann BD, Terrian DM, Basecke J, Stivala F, Libra M, Evangelisti C, Martelli AM. McCubrey JA, et al. Among authors: stivala f. Adv Enzyme Regul. 2007;47:64-103. doi: 10.1016/j.advenzreg.2006.12.013. Epub 2007 Mar 26. Adv Enzyme Regul. 2007. PMID: 17382374 Free PMC article. No abstract available.
Akt as a therapeutic target in cancer.
Steelman LS, Stadelman KM, Chappell WH, Horn S, Bäsecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA. Steelman LS, et al. Among authors: stivala f. Expert Opin Ther Targets. 2008 Sep;12(9):1139-65. doi: 10.1517/14728222.12.9.1139. Expert Opin Ther Targets. 2008. PMID: 18694380 Review.
Emerging Raf inhibitors.
McCubrey JA, Steelman LS, Abrams SL, Chappell WH, Russo S, Ove R, Milella M, Tafuri A, Lunghi P, Bonati A, Stivala F, Nicoletti F, Libra M, Martelli AM, Montalto G, Cervello M. McCubrey JA, et al. Among authors: stivala f. Expert Opin Emerg Drugs. 2009 Dec;14(4):633-48. doi: 10.1517/14728210903232633. Expert Opin Emerg Drugs. 2009. PMID: 19715444 Review.
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Cocco L, Martelli AM. McCubrey JA, et al. Among authors: stivala f. J Cell Physiol. 2011 Nov;226(11):2762-81. doi: 10.1002/jcp.22647. J Cell Physiol. 2011. PMID: 21302297 Review.
107 results